Disease Activity During Pregnancy and Postpartum in Women With Multiple Sclerosis Treated With Ocrelizumab or Rituximab Before Pregnancy
Nadine Bast, Karen Dost-Kovalsky, Sabrina Haben, Laura Witt, Ralf Gold, Sandra Thiel, Kerstin Hellwig · 2026
Read Disease Activity During Pregnancy and Postpartum in Women With Multiple Sclerosis Treated With Ocrelizumab or Rituximab Before Pregnancy by Nadine Bast, Karen Dost-Kovalsky, Sabrina Haben, Laura Witt, Ralf Gold, Sandra Thiel, Kerstin Hellwig (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13676277.txt.
Description
Nadine Bast and co-authors track multiple sclerosis activity in 2026 in women who stopped two strong drugs for pregnancy. Both drugs are often paused before conception, yet how washout time and total dose affect relapse was unclear.
A German registry held records of nearly three hundred pregnancies in women treated with one of the drugs before pregnancy. Most women had their last dose less than four months before their last period, and most had at least two cycles. Relapses were rare during pregnancy and in the year after birth. Lasting disability after birth was also rare. Neither washout time nor cycle count linked to a higher relapse risk.
Catalog record
| CREATOR | Nadine Bast, Karen Dost-Kovalsky, Sabrina Haben, Laura Witt, Ralf Gold, Sandra Thiel, Kerstin Hellwig |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 47 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |